A setback to analysis that supplied hope for Fibrous Dysplasia sufferers — Harvard Gazette

In 2023, the Harvard School of Dental Medicine was awarded a U.S. Department of Defense grant to fund a four-year research of fibrous dysplasia (FD), a extreme skeletal illness through which benign tumors trigger bone deformities, fractures, and ache. The award aimed to research the mobile and molecular underpinnings of the illness, which impacts an estimated 1 in 15,000 to 30,000 folks and presently has no remedy. The analysis had promise not just for treating FD, but in addition for locating remedies for circumstances affecting navy personnel, together with blast-induced heterotopic ossification and continual bone ache.

At the time, the funding was applauded by sufferers and affected person advocacy teams corresponding to FD/MAS Alliance, a nonprofit devoted to discovering evidence-based remedies for Fibrous Dysplasia and McCune-Albright syndrome.

“This funding was more than just a financial award—it was a crucial investment in understanding and eventually treating a devastating disease,” mentioned Adrienne McBride, govt director of the Alliance. “Advancing research in FD/MAS benefits those living with this rare disease and holds great potential for broader medical applications.”

The mechanisms investigated in FD analysis have the potential to yield insights related for a lot of different ailments inflicting bone fragility, ache, and fractures. With federal analysis funding to Harvard now frozen, these insights could by no means be realized.

“FD patients and their families had been closely following research advances, hoping for novel, effective interventions. The termination of leading-edge projects like this erodes this hope and sends a discouraging signal to those living with an already-overlooked disease,” mentioned Yingzi Yang, professor of Developmental Biology at HSDM, and principal investigator on the grant.

Yang and her companions at Massachusetts General Hospital (MGH) had been making progress within the few years for the reason that funding was awarded. While some work continues at MGH, the analysis primarily based within the Yang Lab at HSDM, which was vital to offering a better understanding of the illness mutation, has stopped.

“We had made substantial progress in terms of identifying potential treatment targets of this devastating disease based on getting a better understanding of the molecular mechanisms,” mentioned Yang. “Cutting off our study disrupts the holistic understanding of the FD disease and reduces the research rigor and impacts.”

“The cancellation of this grant is a significant setback for FD/MAS research and for patients, including military personnel, who rely on scientific progress for hope and support,” mentioned McBride.

FD/MAS can have an effect on each bone within the physique, however the largest subpopulation of these with the illness are affected by FD lesions of their craniofacial bones, resulting in extreme facial deformities. 

HSDM alumnus Christopher H. Fox, DMD87, DMSc91, who leads the American Association for Dental, Oral, and Craniofacial Research (AADOCR), additionally expressed deep considerations over the implications.

“This funding cut of such promising research is a tragedy for the FD/MAS community and indeed for our country.  Through our advocacy efforts, AADOCR is doing everything we can to reverse these ill-advised decisions,” mentioned Fox.